Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Keeping An Eye On Regeneron: What's Next To Drive Growth

Executive Summary

Regeneron is looking to expansion of Eylea to diabetic retinopathy and Dupixent to asthma and other indications to drive mid-term growth. The firm is poised to file a PD-1 inhibitor with FDA in Q1.

Advertisement

Related Content

Regeneron Tries To Put Focus On PD-1 Program, Not Sluggish Autoimmune Sales
PANORAMA Helps Regeneron's Eylea Even Score With Roche's Lucentis
Sanofi Sees Cemiplimab As Path To Relevance In Immuno-Oncology
Outcomes Claim May Help Amgen Make Case For PCSK9 Inhibitor Repatha
Regeneron On Genetics R&D: 'It's Our Oxygen'
Sanofi Ready To Pull The Plug On Regeneron 'Life Support'
Sanofi and Regeneron Hit Asthma Phase III Endpoints With Dupixent
Sanofi/Regeneron Choose Access Over Price With Dupixent Launch
Sanofi Oncology Strategy: A New Lease On Cancer R&D

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

SC099846

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel